从行业市盈率排名来看，公司所处的医疗器械行业市盈率平均56.58倍，行业中值39.97倍，山外山排名 第95位。 最新一期业绩显示，2025年一季报，公司实现营业收入1.89亿元，同比16.77%；净利润3700.64万元， 同比8.10%，销售毛利率46.72%。 序号股票简称PE(TTM)PE(静)市净率总市值(元)13山外山75.7378.693.2355.78亿行业平均 56.5852.305.00119.53亿行业中值39.9739.072.9157.03亿1九安医疗11.3611.490.89191.70亿2英科医疗 15.6416.861.39247.04亿3山东药玻16.2816.331.87154.02亿4新华医疗16.6315.411.36106.59亿5奥美医疗 17.1216.781.7661.87亿6振德医疗17.3816.381.1163.10亿7九强生物17.7016.462.1787.65亿8康德莱 18.0418.051.4938.87亿9维力医疗18.5219.782.3343.40亿10奥泰生物18.7119.731.5159.67亿11鱼跃医疗 20.2019.812. ...

最新一期业绩显示，2025年一季报，公司实现营业收入1.89亿元，同比16.77%；净利润3700.64万元， 同比8.10%，销售毛利率46.72%。 序号股票简称PE(TTM)PE(静)市净率总市值(元)13山外山74.5977.513.1854.94亿行业平均 55.7651.784.91117.92亿行业中值39.1439.592.8556.79亿1九安医疗11.1811.310.88188.72亿2英科医疗 14.7815.931.32233.49亿3山东药玻16.1716.211.86152.90亿4新华医疗16.3115.111.33104.53亿5振德医疗 17.0416.061.0861.87亿6奥美医疗17.0716.731.7561.68亿7九强生物17.6516.412.1687.42亿8康德莱 18.2218.241.5139.27亿9奥泰生物18.4419.441.4958.81亿10维力医疗18.4719.732.3243.29亿11鱼跃医疗 20.1919.802.73357.58亿12安图生物20.6219.682.65235.08亿 来源：金融界 截至2025年一季报，共有 ...

Group 1 - The core viewpoint of the articles highlights the performance and valuation of Chongqing Shanwaishan Blood Purification Technology Co., Ltd., particularly its stock price, market capitalization, and industry comparisons [1][2]. - As of August 8, the company's stock closed at 16.56 yuan, reflecting a 2.79% increase, with a rolling PE ratio of 72.24, marking a new low in 11 days, and a total market capitalization of 5.321 billion yuan [1]. - The average PE ratio for the medical device industry is 55.70, with a median of 39.08, positioning Shanwaishan at the 93rd rank within the industry [1][3]. Group 2 - Chongqing Shanwaishan specializes in the research, production, and sales of blood purification equipment and consumables, as well as providing chain blood dialysis medical services [2]. - The company's main products include blood perfusion machines, continuous blood purification devices, and various types of dialysis machines and consumables [2]. - In the latest quarterly report for Q1 2025, the company reported revenue of 189 million yuan, a year-on-year increase of 16.77%, and a net profit of 37.064 million yuan, reflecting a year-on-year growth of 8.10%, with a gross profit margin of 46.72% [2].

Group 1 - The closing price of the company on July 24 was 15.54 yuan, an increase of 2.71%, with a rolling PE ratio of 67.79, marking a new low in 255 days, and a total market value of 4.993 billion yuan [1] - The average PE ratio in the medical device industry is 54.56, with a median of 37.54, placing the company at the 92nd position in the industry ranking [1] - As of the first quarter of 2025, 11 institutions held shares in the company, all being funds, with a total holding of 6.3098 million shares valued at 0.09 billion yuan [1] Group 2 - The main business of the company is the research, production, and sales of blood purification equipment and consumables, along with providing chain blood dialysis medical services [2] - The company's key products include blood perfusion machines, continuous blood purification devices, and various types of dialysis machines and consumables [2] - The company achieved a revenue of 189 million yuan in the first quarter of 2025, representing a year-on-year increase of 16.77%, and a net profit of 37.064 million yuan, up 8.10%, with a gross profit margin of 46.72% [2]

Group 1 - The core business of the company is the research, production, and sales of blood purification equipment and consumables, as well as providing chain blood dialysis medical services [2] - The company has received multiple national and departmental awards for its projects, including the National Science and Technology Progress Award (Second Class) [2] - As of March 31, 2025, the company had a total market capitalization of 4.437 billion yuan and a rolling price-to-earnings (PE) ratio of 60.24, which is higher than the industry average of 51.05 [1][3] Group 2 - The latest quarterly report for Q1 2025 shows the company achieved a revenue of 189 million yuan, representing a year-on-year increase of 16.77%, and a net profit of 37.064 million yuan, with a year-on-year increase of 8.10% [2] - The company's gross profit margin stands at 46.72% [2] - The average PE ratio in the medical device industry is 51.05, with a median of 36.62, positioning the company at the 90th rank within the industry [1][3]

Core Viewpoint - The company Sichuan Ruijian Medical Technology Co., Ltd. (referred to as "Ruijian Medical") has submitted its initial public offering (IPO) application to the Beijing Stock Exchange, aiming to raise 482 million yuan, with significant connections to Lepu Medical [1][2]. Group 1: Company Overview - Ruijian Medical, established in August 2013, transitioned to a joint-stock system in 2016 and was listed on the New Third Board before being delisted in 2018. It was acquired by Hong Kong-listed company Puhua Heshun in 2021, which now controls 50.55% of Ruijian Medical [2]. - The actual controllers of Ruijian Medical are Pu Zhongjie and his mother-in-law Yufeng Liu, who is the ultimate controlling shareholder of Puhua Heshun [2]. Group 2: Financial Performance - Ruijian Medical's revenue from 2021 to the first nine months of 2024 was 2.61 billion yuan, 3.45 billion yuan, 4.11 billion yuan, and 3.42 billion yuan, respectively. The net profit for the same periods was 679.32 million yuan, 1.04 billion yuan, 1.46 billion yuan, and 926.27 million yuan [5][6]. - The company reported a revenue increase of 17.63% for 2024, reaching 4.83 billion yuan, but net profit and net profit excluding non-recurring items decreased by 12.63% and 5.88%, respectively, marking the first instance of revenue growth without profit growth in three years [5][6]. Group 3: Related Party Transactions - Ruijian Medical engaged in significant related party transactions, selling goods worth a total of 202 million yuan to related parties from 2021 to the first nine months of 2024, with Lepu Medical being a major customer [3][4]. - The company also had arrangements for salary payments with related parties, with amounts paid on behalf of employees totaling 116.96 million yuan, 131.09 million yuan, 148.55 million yuan, and 53 million yuan over the reporting periods [3][4]. Group 4: Market Dynamics - The implementation of volume-based procurement has led to a noticeable decline in the sales prices of Ruijian Medical's main products, with the average selling price of blood dialysis machines and blood perfusion devices dropping by over 10% from 2021 to the first nine months of 2024 [5][7]. - The sales prices for blood dialysis machines were 31.21 yuan, 30.83 yuan, 30.1 yuan, and 27.37 yuan, while blood perfusion devices were priced at 169.41 yuan, 164.14 yuan, 159.81 yuan, and 147.32 yuan during the same periods, reflecting a decline of approximately 12.3% and 13%, respectively [7]. Group 5: Future Plans - Ruijian Medical plans to issue up to 43 million new shares to raise a total of 482 million yuan, which will be allocated to projects related to high-value consumables for blood purification, new blood purification equipment, and the establishment of an innovative research center [7].